JP2025517356A5 - - Google Patents

Info

Publication number
JP2025517356A5
JP2025517356A5 JP2024568250A JP2024568250A JP2025517356A5 JP 2025517356 A5 JP2025517356 A5 JP 2025517356A5 JP 2024568250 A JP2024568250 A JP 2024568250A JP 2024568250 A JP2024568250 A JP 2024568250A JP 2025517356 A5 JP2025517356 A5 JP 2025517356A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
individual
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024568250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/067146 external-priority patent/WO2023225577A1/en
Publication of JP2025517356A publication Critical patent/JP2025517356A/ja
Publication of JP2025517356A5 publication Critical patent/JP2025517356A5/ja
Pending legal-status Critical Current

Links

JP2024568250A 2022-05-18 2023-05-17 抗ｃｄ２２抗体オリゴヌクレオチドコンジュゲートを使用したがんの治療方法 Pending JP2025517356A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263343506P 2022-05-18 2022-05-18
US63/343,506 2022-05-18
PCT/US2023/067146 WO2023225577A1 (en) 2022-05-18 2023-05-17 Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates

Publications (2)

Publication Number Publication Date
JP2025517356A JP2025517356A (ja) 2025-06-05
JP2025517356A5 true JP2025517356A5 (enExample) 2026-05-18

Family

ID=88836107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024568250A Pending JP2025517356A (ja) 2022-05-18 2023-05-17 抗ｃｄ２２抗体オリゴヌクレオチドコンジュゲートを使用したがんの治療方法

Country Status (6)

Country Link
US (1) US20260115309A1 (enExample)
EP (1) EP4525930A1 (enExample)
JP (1) JP2025517356A (enExample)
KR (1) KR20250039518A (enExample)
CN (1) CN119546345A (enExample)
WO (1) WO2023225577A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025081048A1 (en) * 2023-10-13 2025-04-17 Tallac Therapeutics, Inc. Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates
CN120324454A (zh) * 2024-01-17 2025-07-18 安升（上海）医药科技有限公司 多肽-寡核苷酸复合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021007294A2 (pt) * 2018-10-17 2021-07-27 Tallac Therapeutics, Inc. imunomodulação de conjugados de polinucleotídeos e métodos de uso
US11920136B2 (en) * 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
WO2022040173A1 (en) * 2020-08-18 2022-02-24 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
MX2024002407A (es) * 2021-08-25 2024-05-15 Tallac Therapeutics Inc Anticuerpos y conjugados sirp-alfa.

Similar Documents

Publication Publication Date Title
JP2021058197A5 (enExample)
TW202034959A (zh) 抗體-藥物結合物與parp抑制劑之組合
JP2023539715A5 (enExample)
JP2022095908A5 (enExample)
JP2021513541A5 (enExample)
JPWO2020122034A5 (enExample)
JP2018537975A5 (enExample)
JP2020515578A5 (enExample)
TW202019487A (zh) 抗體-藥物結合物及微管蛋白抑制劑之組合
CN111132696B (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
JP2010535713A5 (enExample)
TW201922793A (zh) Ｐｄ－１抗體和ｖｅｇｆｒ抑制劑聯合治療小細胞肺癌的用途
JP2023545096A5 (enExample)
JP2021515017A5 (enExample)
JP2020500834A5 (enExample)
JP2021511372A5 (enExample)
JP2018512402A5 (enExample)
JP2019524713A5 (enExample)
TW202330040A (zh) 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
JP2022541591A5 (enExample)
CN116712539A (zh) 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途
JP2025509266A5 (enExample)
EP4464337A1 (en) Combined use of anti-trop-2 antibody-drug conjugate and other therapeutic agents
WO2021129616A1 (zh) 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
CN118201963A (zh) 用于治疗非小细胞肺癌的药物组合